A Virtual Intervention to Improve Medication Adherence in Pediatric Cancer: MedSupport

Medication Adherence Clinical Trial

Official title:

A Virtual Intervention to Improve Medication Adherence in Pediatric Cancer: MedSupport

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05150028
• Other study ID #: I 2048021
• Status: Active, not recruiting
• Phase: N/A
• Start date: April 11, 2023
• Est. completion date: June 6, 2024

Study information

• Verified date: September 2023
• Source: Roswell Park Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To develop a cancer center level practice intervention to promote treatment adherence and reduce outcome disparities in pediatric cancer survivors

Description:

To conduct a pilot study to assess the feasibility and acceptability of the Social Determinants of Adherence intervention

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 17
• Est. completion date: June 6, 2024
• Est. primary completion date: June 6, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 1 Year and older

Eligibility

Inclusion Criteria:

Parents/caregivers of pediatric patients must meet the following criteria to be eligible:

• Parents/guardians of child that has been diagnosed with any cancer.
• Parents/guardians of child with any cancer between age 0 and 18.
• Parents/guardians of child on home-based oral anti-cancer therapy or supportive care therapy.
• The clinician for the family agrees to participate in the study.

Exclusion Criteria:

• Participants will be excluded from this study if unwilling or unable to complete the assessment in English

Related Conditions & MeSH terms

• Medication Adherence

Intervention

Behavioral:
• Patient participation
Questionnaire

Other:
• Clinician barrier reports
How many times a 7 question Survey on medication education practices is opened

Locations

Country	Name	City	State
United States	Roswell Park Cancer Institute	Buffalo	New York

Sponsors (1)

Lead Sponsor	Collaborator
Roswell Park Cancer Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Retention rates	Feasibility of intervention as assessed by retention rates	Up to 8 weeks
Secondary	Feasibility of universal SDOA screening	Will be assessed by results of SDOA questionnaire an 8 item questionnaire rated on a 5-point Likert scale (0-I never experienced this ; 5 - I experience this quite a lot)	up to 8 weeks
Secondary	Provider satisfaction with barrier reports	REDCap analytics will track the rate of opened barrier reports	up to 8 weeks